HealthcareServices

Global Diabetic Peripheral Neuropathy Market 2026–2030: Forecast Insights for Business Planning

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the diabetic peripheral neuropathy market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Diabetic Peripheral Neuropathy Market expected to reach by 2030?

The diabetic peripheral neuropathy market size has shown significant growth in recent years. It is anticipated to increase from $3.83 billion in 2025 to $4.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to the high occurrence of diabetic nerve damage, delayed clinical intervention, limited awareness of early symptoms, a reliance on analgesics, and the increasing duration of diabetes.

The diabetic peripheral neuropathy market size is projected to experience substantial growth in the coming years. It is anticipated to reach $5.84 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.8%. The expansion during this forecast period can be attributed to advancements in screening technologies, the growth of specialty care centers, the development of novel pain therapies, enhanced patient education, and a rising elderly diabetic population. Key trends expected in the forecast period include an increasing demand for peripheral neuropathy treatments, a greater emphasis on early sensory loss detection, the expansion of combination pain management solutions, the rising adoption of long-term symptom control therapies, and intensified patient screening and monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp

What Drivers Are Driving Adoption Within The Diabetic Peripheral Neuropathy Market?

A rise in health problems linked to obesity is projected to boost the expansion of the diabetic peripheral neuropathy market in the future. Obesity is defined as a medical state where excessive body fat gathers, potentially harming health and elevating the likelihood of numerous chronic illnesses. This surge in obesity-associated health concerns stems from heightened public understanding, evolving lifestyles, and an increasing demand for preventative measures and therapeutic options, consequently driving up healthcare requirements. Diabetic peripheral neuropathy plays a beneficial role in managing obesity. It offers crucial understanding regarding nerve damage resulting from obesity-related ailments, thereby directing specific interventions to enhance patients’ overall health and their standard of living. For example, in September 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, indicated that 23 states reported an adult obesity prevalence of 35% or greater in 2023, with all 50 states showing obesity rates of at least 20%. Consequently, the growing number of health issues associated with obesity is stimulating expansion within the diabetic peripheral neuropathy market.

How Is The Diabetic Peripheral Neuropathy Market Organized Into Various Segments?

The diabetic peripheral neuropathy market covered in this report is segmented –

1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy

2) By Treatment: Pain Management Drugs, Gene Therapies

3) By Therapy: Antidepressants, Anticonvulsants

4) By Patient Population: Adult Patients, Geriatric Patients

Subsegments:

1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy

2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy

What Trends Are Projected To Support The Growth Of The Diabetic Peripheral Neuropathy Market?

Companies operating in the diabetic peripheral neuropathy market are primarily concentrating on technological breakthroughs, such as NaV1.8 pain signal inhibitors, to deliver advanced, non-opioid treatments to patients that improve pain management and their overall quality of life. A NaV1.8 pain signal inhibitor refers to a specialized medication that works by blocking the NaV1.8 sodium channel, which is a critical mediator of pain signals in sensory neurons, to provide relief from acute and neuropathic pain without the need for opioids. For example, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, revealed advancements in its suzetrigine pain program, including the initiation of a Phase 3 pivotal program for addressing pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has exhibited promising results in prior studies and recently secured breakthrough therapy designation from the Food and Drug Administration (FDA), a US-based federal agency, for diabetic Peripheral Neuropathy (DPN) pain management.

Who Are The Primary Competitors In The Global Diabetic Peripheral Neuropathy Market?

Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., NeuroMetrix Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca plc., Bayer AG., UCB SA., Regeneron Pharmaceuticals Inc., Roche., Sanofi S.A., Amgen Inc., Lexicon Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/diabetic-peripheral-neuropathy-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Diabetic Peripheral Neuropathy Market?

North America was the largest region in the diabetic peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Diabetic Peripheral Neuropathy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21170&type=smp

Browse Through More Reports Similar to the Global Diabetic Peripheral Neuropathy Market 2026, By The Business Research Company

Non Proliferative Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795